Brief Communication abstract
Nature Medicine 13, 1032 - 1034 (2007)
Published online: 26 August 2007 | doi:10.1038/nm1624
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
Yuxing Li1, Stephen A Migueles2, Brent Welcher1, Krisha Svehla1, Adhuna Phogat1, Mark K Louder1, Xueling Wu1, George M Shaw3, Mark Connors2, Richard T Wyatt1,4 & John R Mascola1,4
We have identified several patient sera showing potent and broad HIV-1 neutralization. Using antibody adsorption and elution from selected gp120 variants, the neutralizing specificities of the two most broadly reactive sera were mapped to the primary receptor CD4–binding region of HIV-1 gp120. Novel antibodies to the CD4-binding site are elicited in some HIV-1–infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Departments of Medicine and Microbiology, University of Alabama, Birmingham, Alabama 35294, USA.
- These authors contributed equally to this work.
Correspondence to: Richard T Wyatt1,4 e-mail: richardwyatt@nih.gov
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Targeting Pemphigus Autoantibodies through their Heavy-Chain Variable Region GenesJournal of Investigative Dermatology Original Article
Targeting Pemphigus Autoantibodies through their Heavy-Chain Variable Region GenesJournal of Investigative Dermatology Original Article
HIV/AIDS Vaccines: 2007Clinical Pharmacology & Therapeutics Article Response
HIV/AIDS Vaccines: 2007Clinical Pharmacology & Therapeutics Article Response
See all 18 matches for Research